Reshma Rangwala - 20 Apr 2023 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Signature
/s/Nancy Smith as Attorney-in-Fact for Reshma Rangwala
Issuer symbol
KPTI
Transactions as of
20 Apr 2023
Net transactions value
-$27,416
Form type
4
Filing time
24 Apr 2023, 18:09:25 UTC
Previous filing
02 Mar 2023
Next filing
25 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale $463 -115 -0.07% $4.03 164,885 20 Apr 2023 Direct F1
transaction KPTI Common Stock Sale $26,953 -6,655 -4% $4.05 158,230 20 Apr 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.